12522677

Source:http://linkedlifedata.com/resource/pubmed/id/12522677

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0007257, umls-concept:C0008838, umls-concept:C0013216, umls-concept:C0017636, umls-concept:C0028096, umls-concept:C0030705, umls-concept:C0079083, umls-concept:C0348016, umls-concept:C1518321, umls-concept:C1561451
pubmed:issue	5
pubmed:dateCreated	2003-1-10
pubmed:abstractText	Thirty glioblastoma patients treated at our institute between April 1998 and September 1999 were randomized in a two-arm study to receive carboplatin plus ACNU intraarterial (IA) chemotherapy (arm A) or cisplatin plus BCNU intravenous (IV) treatment (arm B). After the second course of chemotherapy and before the third cycle they also received concomitant radiotherapy, consisting of a median dose of 56.5 Gy. There were 3 (21.4%) partial responses and 11 (78.6%) disease stabilizations in group A. There were 5 (33%) partial responses and 10 disease stabilizations in group B. Time to tumor progression was 5.2 and 5.8 months for IA and IV treatment respectively. Median survival time was 18.3 months for arm A patients and 18.6 for arm B patients. Our IA chemotherapy schedule has produced no conclusive evidence of benefit compared with intravenous treatment. Moreover, its cost-benefit ratio is not good enough to justify its continued pursuit.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/100959175
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Carboplatin, http://linkedlifedata.com/resource/pubmed/chemical/Carmustine, http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Nimustine
pubmed:status	MEDLINE
pubmed:month	Dec
pubmed:issn	1590-1874
pubmed:author	pubmed-author:BoiardiAA, pubmed-author:CrosM LML, pubmed-author:ErbettaAA, pubmed-author:FariselliLL, pubmed-author:SalmaggiAA, pubmed-author:SilvaniAA
pubmed:issnType	Print
pubmed:volume	23
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	219-24
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:12522677-Adolescent, pubmed-meshheading:12522677-Adult, pubmed-meshheading:12522677-Aged, pubmed-meshheading:12522677-Antineoplastic Agents, pubmed-meshheading:12522677-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12522677-Carboplatin, pubmed-meshheading:12522677-Carmustine, pubmed-meshheading:12522677-Cisplatin, pubmed-meshheading:12522677-Drug Administration Routes, pubmed-meshheading:12522677-Female, pubmed-meshheading:12522677-Glioblastoma, pubmed-meshheading:12522677-Humans, pubmed-meshheading:12522677-Injections, Intra-Arterial, pubmed-meshheading:12522677-Injections, Intravenous, pubmed-meshheading:12522677-Karnofsky Performance Status, pubmed-meshheading:12522677-Male, pubmed-meshheading:12522677-Middle Aged, pubmed-meshheading:12522677-Nimustine
pubmed:year	2002
pubmed:articleTitle	Intra-arterial ACNU and carboplatin versus intravenous chemotherapy with cisplatin and BCNU in newly diagnosed patients with glioblastoma.
pubmed:affiliation	Department of Neuro-oncology, Istituto Nazionale Neurologico Carlo Besta, Via Celoria 11, I-20133 Milan, Italy.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Clinical Trial, Phase II